For decades, the scientific community has recognized total tau (t-tau), phosphorylated tau (p-tau), and Aβ42 (Aβ42) as biomarkers for Alzheimer’s disease (AD) diagnosis (Blennow et al., 2010; Balasa et al., 2014). The gene discussed is MAPT; the disease is early-onset autosomal dominant Alzheimer disease.